A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
- Registry ID
- EUCTR2014-002940-42
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- GW Research Ltd
- Start date
- 2014-11-10
- Completion date
- 2016-05-02
- Last update
- 2026-08-16
Conditions
- Lennox-Gastaut syndrome (LGS)
Summary
To evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures, when compared with placebo in patients with LGS.
Drop seizure is defined as an attack or spell (atonic, tonic, or tonic-clonic) involving the entire body, trunk or head that led or could have led to a fall, injury, slumping in a chair or hitting the patient’s head on a surface.
Locations
View on source registry